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Abstract
Biodegradable core-shell structured nanoparticles with a poly(β-amino-ester) (PBAE) core
enveloped by a phospholipid bilayer shell were developed for in vivo mRNA delivery, with a view
toward delivery of mRNA-based vaccines. The pH-responsive PBAE component was chosen to
promote endosome disruption, while the lipid surface layer was selected to minimize toxicity of
the polycation core. Messenger RNA was efficiently adsorbed via electrostatic interactions onto
the surface of these net positively-charged nanoparticles. In vitro, mRNA-loaded particle uptake
by dendritic cells (DCs) led to mRNA delivery into the cytosol with low cytotoxicity, followed by
translation of the encoded protein in these difficult-to-transfect cells at a frequency of ~30%.
Particles loaded with mRNA administered intranasally in mice led to the expression of the reporter
protein luciferase in vivo as soon as 6 h after administration, a timepoint when naked mRNA
given i.n. showed no expression. At later timepoints, luciferase expression was detected in naked
mRNA-treated mice, but this group showed a wide variation in levels of transfection, compared to
particle-treated mice. This system may thus be promising for non-invasive delivery of mRNA-
based vaccines.
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Introduction
Gene-based vaccination was born in 1990 after Wolff et al. demonstrated the local uptake
and expression of exogenously injected plasmid DNA and in vitro transcribed messenger
RNA (mRNA),1 followed shortly thereafter by the demonstration that injected nucleic acids
could promote immune responses to encoded antigens.2,3 Both DNA and mRNA-based
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vaccines share many advantages over alternative protein, peptide, or live vector-based
vaccine strategies in terms of safety, manufacturability and suitability for long-term storage,
and the ability to promote broad cytotoxic T-cell responses.4,5 Since the first
demonstrations, DNA-based vaccines have undergone extensive preclinical and clinical
testing, while mRNA-based therapies remained less thoroughly investigated. However,
DNA vaccines have failed to show potency in large-animal models and humans, in discord
from results in small-animal studies,6 which may reflect in part the difficulty of overcoming
not only the barrier posed by the plasma membrane of cells but also the need to transport
DNA through the nuclear membrane of non-dividing cells. Vaccines based on mRNA, by
contrast, require nucleic acid delivery only to the cytosol, thereby allowing the transfection
of quiescent and post-mitotic cells that comprise the majority of target cells in vivo.7,8
To deliver macromolecules intracellularly, synthetic vectors are preferred over approaches
based on viral vectors for their low cost, ease of large-scale production and potential for
improved safety.9–12 To date, strategies reported for non-viral delivery of mRNA for
vaccines and gene therapy applications include injection of naked mRNA,1,4
polyplexes,13,14 lipoplexes or liposome-entrapped mRNA,15,16 bolistic delivery via gene
gun,17,18, particulate carrier-mediated delivery19 and electroporation.20–22 Recently, clinical
trials in which human patients were vaccinated with naked or protamine-complexed mRNA
against tumor antigens via intradermal injections were completed, demonstrating feasibility,
lack of toxicity and promising responses based on clinical and immunological read-outs.23,24
However, more efficient transfection in vivo, and the ability to deliver these nucleic acids
non-invasively and/or to mucosal sites, would be expected to enhance the prospects of this
strategy for vaccination.
A variety of polymer and/or lipid-based drug delivery systems with the capability to disrupt
endosomes have been developed that might be applicable for mRNA vaccine delivery25–29,
but systems that achieve efficient cytosolic delivery or transfection in vivo with minimal
cytoxicity are still sought. For vaccine applications, cytosolic delivery of mRNA into
dendritic cells (DCs), immune cells that play a key role in the initiation of adaptive immune
responses30, is desired but the transfection of these cells poses a significant challenge as
synthetic agents generally achieve only 10–35% transfection of these cells in vitro.31–33 We
previously reported a pH-responsive core-shell nanoparticle system prepared by sequential
emulsion polymerization of a secondary-amine-containing monomer (diethlyaminoethyl
methylacrylate) forming a pH-responsive core, followed by a second monomer (aminoethyl
methacrylate) forming a hydrophilic corona.34,35 The core-shell particle structure enabled
the physical and compositional segregation of the functions for the particle into an
endosome-disrupting pH-responsive core and a shell whose composition could be separately
tuned to facilitate particle targeting, cell binding, and/or drug binding. These particles
efficiently delivered associated protein or oligonucleotide cargos to the cytosol of dendritic
cells through endosomal disruption mediated by the core polymer via the proton-sponge
effect, while maintaining low cytotoxicity by sequestering the cationic charge and
hydrophobicity of the polymer core within a more hydrophilic polymeric shell. However, a
limitation of this proof-of-concept system is its lack of biodegradability, which hinders
clinical translation.
Here we adapted our core-shell design approach to a fully degradable system comprised of a
pH-responsive poly(β-amino-ester) (PBAE) core and a phospholipid shell. As a first step
toward enhanced mRNA vaccines, we show that negatively-charged mRNA can be adsorbed
via electrostatic interactions onto the surface of these cationic nanoparticles, protecting the
nucleic acids from degradation in serum. Lipid-enveloped PBAE particles disrupted
endosomes and delivered mRNA into the cytosol of DCs with minimal cytotoxicity, leading
to in vitro transfection of a DC clone at levels comparable to the best reports for DC
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transfection from the literature. Importantly, mRNA-loaded lipid-enveloped particles also
promoted in vivo transfection following non-invasive intranasal delivery, suggesting their
potential utility for mRNA vaccine formulations.
Materials and Methods
Materials
The poly(β-amino ester) poly-1 with a number averaged molecular weight of ~10 kDa was
synthesized as previously reported.36 Poly(lactide-co-glycolide) (PLGA) with a 50:50
lactide:glycolide ratio and molecular weight of ~46 kDa was purchased from Lakeshore
Biomaterials (Birmingham, AL). The lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) (DOTAP), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethyleneglycol) -2000]
(ammonium salt) (DSPE-PEG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy-(polyethyleneglycol)-2000-N′-carboxyfluorescein] (ammonium salt) (DSPE-
PEG-CF) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B
sulfonyl) (ammonium salt) (DOPE-rhodamine) were purchased from Avanti Polar Lipids
(Alabaster, AL). Poly(vinyl-alcohol) (PVA) with a molecular weight of ~78 kDa was
purchased from Polysciences Inc. (Warrington, PA). Calcein, DAPI and sodium acetate
buffer were purchased from Sigma Chemical Co. (St. Louis, MO). Triton X-100 (molecular
biology grade) was from Promega Corp. (Madison, WI). Poly (L-aspartic acid) (sodium salt)
was from Alamanda Polymers (Huntsville, AL). 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD), Annexin V Alexa 350
conjugate, LysoTracker Green, ribogreen and SYBR Green II RNA gel stain were purchased
from Invitrogen (Eugene, OR). Poly I:C was purchased from InvivoGen (San Diego, CA).
RNAse inhibitor was purchased from Roche (Indianapolis, IN). D-Luciferin (potassium salt)
was from Caliper Life Sciences (Hopkinton, MA). Cy3 Label ITR nucleic acid labeling kit
was purchased from Mirus Bio LLC (Madison, WI). All materials were used as received
unless otherwise noted.
Synthesis and Characterization of Lipid-coated PBAE Nanoparticles
Lipid-coated nanoparticles with a poly-1 core were synthesized via two different processes:
a double emulsion/solvent evaporation approach or a solvent diffusion/nanoprecipitation
strategy. For double emulsion synthesis, we adapted a previous approach we used for
preparing lipid-enveloped PLGA particles37: 30 mg of poly-1 (or PLGA for pH-insensitive
control particles) and 2 mg of the phospholipids DOPC, DOTAP, and DSPE-PEG in a 7:2:1
molar ratio were co-dissolved in 1 ml of dicholoromethane (DCM). PBS (200 μl) was then
added to the mixture on ice during a 1 min sonication step at 7 W using a probe tip sonicator
(Misonix XL2000, Farmingdale, NY) to form a first emulsion. The primary emulsion was
then dispersed into 6 ml of distilled, deionized nuclease-free water with sonication at 12 W
for 5 min, before leaving on a shaker for 18 h at 25 °C to evaporate the organic solvent. For
nanoprecipitation synthesis, the same quantities of DOPC, DOTAP, and polymer were co-
dissolved in 4 ml of ethanol and added drop-wise to 40 ml of distilled, deionized nuclease-
free water, followed by gentle stirring for 5 h to evaporate ethanol. For particles prepared by
nanoprecipitation, we found that adding DSPE-PEG in the organic phase together with
DOPC, DOTAP and polymer reduced particle yield significantly, so DSPE-PEG was
introduced into the lipid coating via a post-insertion process: DSPE-PEG lipid was added at
1 mM to 0.5 mg/ml particles in distilled, deionized nuclease-free water and the suspension
was stirred for 16 h at 25 °C. The particles were collected and washed once via
centrifugation, resuspended in fresh water and stored at 4 °C until use. Lipid-free PVA-
stabilized particles were prepared by similar processes except the organic emulsion or
solution containing polymer only was dispersed into a 2% w/vol PVA aqueous solution.
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A fraction of each particle batch was dried in a vacuum oven to determine the particle
concentration (mg/ml) by measuring the dry mass. Dynamic light scattering (DLS) and zeta
potential measurements were used to determine the particle size and surface charge using a
ZetaPALS dynamic light scattering detector (Brookhaven Instruments). To estimate the
percentage of PEG-lipid incorporated and the resultant mol% of PEG-lipid present in the
lipid surface coating, lipid-enveloped particles were prepared by nanoprecipitation as
described above with 1 mol% DOPE-rhodamine added as a tracer for measuring the total
amount of lipid incorporated into the particles, before the post-insertion of a DSPE-PEG
lipid labeled with carboxyfluorescein (DSPE-PEG-CF). The lipids were then stripped from
the particle surface by treatment with 2% triton X-100 for 15 min and the supernatant was
measured for both rhodamine and fluorescein signals to quantitate the amount of PEG lipid
incorporated.
To investigate the surface structure of lipid-coated PBAE particles by cryoelectron
microscopy (cryoEM), particles were embedded in ice by blotting a particle suspension (3
uL) on a 1.2/1.3 μm holey carbon-coated copper grid (Electron Microscopy Sciences) and
immediately freezing the sample in liquid ethane using a Leica plunge-freezing machine.
Samples were transferred to a cryogenic holder and imaged using a JEOL 2200FS
transmission electron microscope at 185 μA emission current and 40 000× magnification.
Analysis of Endosomal Disruption
The dendritic cell clone DC2.4 (gift from Prof. Kenneth Rock) was plated at 1.2 × 105 cells/
well in Lab-Tek chambers (Nunc) for 18h, and then calcein (150 μg/ml, 0.24 mM) was
added to the cells with or without 75 μg/ml of lipid-coated nanoparticles containing either a
poly-1 or PLGA core in RPMI 1640 complete medium (10% fetal bovine serum (FBS),
5mM L-glutamine, 10mM HEPES, and penicillin/streptomycin) for 1 h at 37 °C. After
washing with medium to remove extracellular calcein/particles, the cells were imaged live
under a confocal microscope (Zeiss LSM 510) at 63x. To quantify the percentage of cells
displaying cytosolic/nuclear distribution of calcein, cells were detached with Trypsin/EDTA,
resuspended in flow cytometry buffer (1% BSA, 0.1% NaN3 in Hank’s balanced salt
solution, pH 7.4) and analyzed by flow cytometry, gating on the cell population expressing
high mean fluorescence intensity beyond that exhibited by cells treated with calcein alone.
Cytotoxicity Assay
Cytotoxicity of the particles was assessed by incubating DC2.4 cells (6 × 105 cells/well in
12 well plates seeded 18 h prior to experiments) with 50, 75 or 100 μg/ml of lipid-coated
PBAE particles with or without PEG-lipid incorporation, or PBAE particles stabilized with
poly-vinyl-alcohol (PVA) as surfactant, in complete medium for 1 or 12 h at 37 °C. After
washing with medium to remove extracellular particles, the cells were detached with
Trypsin/EDTA, resuspended in complete medium and rested for 1 h at 37 °C. The cells were
then stained with DAPI and annexin V according to manufacturer’s recommendation to
identify cells undergoing apoptosis and necrosis. The percentage of live cells was quantified
via flow cytometry (BD LSR II) by counting cells that were negative for both stains.
Messenger RNA
Synthetic mRNA was prepared as described previously.38,39 Briefly, linearized plasmid
DNA bearing the T7 promoter, an open reading frame (GFP, 811 nucleotides or firefly
luciferase, 1714 nucleotides), and poly-A tail was used as a template for in vitro
transcription using the Message Machine T7 Ultra Transcription kit (Ambion). The mRNA
product was precipitated with LiCl, resuspended in nuclease-free water, and quantitated with
a NanoDrop spectrophotometer. RNA size, purity and integrity were ascertained with an
Agilient Bioanalyzer 2100. An RMA cell line electroporated with these mRNA transcripts
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was also used to confirm the functionality of these mRNA in vitro (data not shown). mRNA
was labeled with a fluorescent Cy3 tag using a Label IT® nucleic acid labeling kit (Mirus
Bio LLC) according to the manufacturer’s protocol.
RNA Loading and Release
Poly I:C or mRNA were loaded onto the surface of lipid-coated PBAE particles by first
diluting the particle suspension to 1.5 mg/ml in nuclease-free water, then adding 200 μl of
the diluted suspension dropwise to 100 μl containing 4 μg of RNA under gentle vortexing.
The vial was then incubated at 4 °C for 2 h on a rotator to allow RNA adsorption. Bound
RNA was determined indirectly by measuring fluorescence of either Cy3-labeled or
ribogreen-stained RNA remaining in the supernatant after centrifugation of the particles
using a fluorescence plate reader (SPECTRAmax, Molecular Devices Corp.). RNA bound to
the particles was determined by subtracting the quantity of RNA detected in the supernatant
from the quantity measured in identically-treated control vials containing RNA solutions but
no particles. To assess the binding kinetics and capacity of the particles, the particle
concentration was fixed at 1 mg/ml while the binding time and RNA amount was varied as
described in the text. Binding efficiency was defined as the percentage of RNA initially
present in solution that bound to the particles. Loading was defined as the amount of RNA
bound (μg) per mg of particles. To determine the release kinetics of bound RNA from
particles in RPMI 1640 culture medium containing 10% FBS, aliquots of particle-adsorbed
poly I:C (70 μg particles containing 1.87 μg poly I:C) were resuspended in 140 μl of serum-
containing-media and incubated at 37 °C under gentle mixing. At each designated time-
point, an aliquot was removed and particles were washed once with nuclease free water
before resuspending in a digestion buffer (100 mM sodium acetate, 2% triton X-100 and 1
mg/ml Poly (L-aspartic acid)) to dissolve the particles and disrupt any lipid-RNA or poly-1-
RNA complexes. The amount of RNA remaining on the particles was then determined by
measuring the fluorescence following staining with ribogreen as above, and the amount of
RNA released was calculated by subtracting the amount of remaining RNA from the original
amount.
RNA Degradation Protection Assay
1 μg of mRNA (encoding for GFP) either naked or loaded onto PEGylated PBAE
nanoparticles was incubated in the presence of 2 or 10% FBS in nuclease free water for 5
min or 1 h at 37 °C. After the incubation period, 100U of RNAse inhibitor was added to
quench degradation and the samples were analyzed by electrophoresis on a 1% agarose gel
at 75V for 1 h. The gel was visualized following staining with SYBR Green II RNA gel
stain according to manufacturer’s protocol.
In Vitro Transfection of DCs
To test whether mRNA loaded onto particles was able to escape from endosomes into the
cytosol, DC2.4 cells were incubated in the presence of a pH-sensitive fluorescent indicator
LysoTracker Green (1 μM) and 1 μg of Cy3-labeled mRNA, either naked mRNA in serum-
free Opti-mem media or the same quantity of labeled mRNA loaded onto PBAE particles
(75 μg particles/ml) in RPMI medium containing 10% FBS. After 1 h, the cells were
washed and imaged live by confocal microscopy.
In vitro transfection of DC2.4 cells was also visualized via fluorescent confocal microscopy
using Cy3-labeled mRNA encoding for green fluorescent protein (GFP). Because mRNA
loading on particles was limited by particle aggregation at high mRNA:particle ratios,
conditions for transfection studies were determined by identifying the maximum
concentration of particles that could be incubated with DCs in vitro without giving rise to
overt cytotoxicity (75 μg particles/ml), and maximizing the amount of the mRNA that could
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be loaded onto this quantity of particles without inducing particle aggregation. This was
determined to be ~4–8 μg of mRNA per 300 μg particles. mRNA-coated lipid-coated PBAE
particles with or without PEGylation (75 μg/ml), loaded with 1 μg of mRNA, were diluted
into RPMI complete medium containing 10% FBS and incubated for 12 h with 6 × 105 cells
seeded in 12-well plates 18 h prior to experiments. mRNA uptake and transfection
efficiency were further assessed by flow cytometry, following rinsing with fresh medium
and trypsinization, to quantify the percentage of cells positive for Cy3 and/or GFP,
compared with control cells incubated with naked mRNA. Particle uptake efficiency was
quantified simultaneously by labeling particles with a lipophilic tracer DiD and measuring
the fraction of cells positive for the tracer.
In Vivo Transfection
Animals were cared for in the USDA-inspected MIT Animal Facility under federal, state,
local and NIH guidelines for animal care. Lipid-coated PBAE particles were tested in vivo
by administering 4 μg of luciferase-encoding mRNA adsorbed to 150 μg particles
intranasally in 20 μl serum-free RPMI medium to anesthetized C57BL/6J mice. Particle
fluorescence and luciferase expression were tracked via bioluminescence imaging following
injection of 300 μl of 15 mg/ml luciferin i.p. in anesthetized mice (Xenogen IVIS Spectrum
Imager).
Statistical Analysis
One-way ANOVA followed by Bonferroni’s Multiple Comparison Test was applied to
determine the significance of the difference between the percentage of cells displaying a
cytosolic/nuclear distribution of calcein with different treatments, as well as the fluorescence
and bioluminescence radiance detected in mice of different treatment groups.
Results and Discussion
Design, Synthesis, and Characterization of Lipid-coated PBAE particles
We previously showed that core-shell structured hydrogel nanoparticles composed of a pH-
responsive proton sponge core and a hydrophilic crosslinked shell could be loaded with
anionic proteins or oligonucleotides by electrostatic adsorption of these cargos to the particle
surfaces.35 Uptake of these core-shell particles by cells led to disruption of acidifying
endolysosomes and efficient delivery of the cargo molecules into the cytosol of cells with
minimal toxicity.34,35 However, these particles were prepared from vinyl monomers and are
effectively non-biodegradable. To translate this proof of concept to a resorbable materials
system for in vivo mRNA delivery, we sought to prepare biodegradable core-shell particles
with the structure schematically outlined in Figure 1A: The particle core is composed of a
pH-sensitive biodegradable poly(β-amino ester) (PBAE), chosen to promote endolysosomal
disruption on particle uptake by cells. We focused on the PBAE poly-1 (Figure 1A) first
synthesized by Lynn et al. and studied for a number of biomedical applications such as drug
and DNA delivery.26,40–42,21,43–45 We sought to surround the poly-1 core by a phospholipid
shell, with the aims of limiting contact of the hydrophobic, cationic polymer core with
cellular constituents prior to degradation and providing a tunable surface to mediate binding
of mRNA to the particle surfaces.
Apropos of this goal, we recently carried out a detailed study of the structure of
nanoparticles formed by an emulsion/solvent-evaporation process, where an organic phase
containing poly(lactide-co-glycolide) (PLGA) polymer co-dissolved with phospholipids was
emulsified in water, followed by evaporation of the organic solvent to form solid polymer
particles.37 In this process, the lipids act as surfactants and self-assemble to form a tightly-
apposed lipid bilayer envelope around each particle.37 We tested whether variations on this
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synthesis strategy could be applied to form lipid-enveloped poly-1 particles: First, we
prepared particles by co-dissolving poly-1 with a mixture of lipids (DOPC:DOTAP 70:20
mol:mol) in dichloromethane (DCM), followed by emulsification of this organic phase in
water and evaporation of the organic solvent. We also tested an approach designed to avoid
the need for toxic DCM, based on nanoprecipitation:46,42,47 PBAE and lipids were co-
dissolved in ethanol, and then dispersed into excess water. In this process, solid PBAE
nanoparticles form as the solvent rapidly diffuses out of the polymer droplets into the
surrounding aqueous phase, leading to the precipitation of the polymer core with lipids
stabilizing the particle surface. For both synthesis strategies, particles were separated from
free liposomes by centrifugation. To promote colloidal stability of particles prepared by
either method, poly(ethylene glycol)-phospholipid conjugates (DSPE-PEG) were introduced
into the bilayer surfaces of the particles during lipid self-assembly (for the double emulsion
process) or by post-insertion48–50 (for nanoprecipitation), resulting in 6–10 mol% PEG-lipid
in the lipid shell. Notably, as discussed below, PEGylation did not affect electrostatic
adsorption of polynucleotides onto the highly charged particle surfaces; but PEGylation did
make the particles resistant to aggregation and easier to resuspend during centrifugation/
washing steps.
Particles prepared by the emulsion/solvent evaporation or nanoprecipitation processes had
similar size distributions as measured by dynamic light scattering (Figure 1B, C), and
similar net positive surface charges indicated by their zeta potentials of 40 ± 9 mV and 42 ±
8 mV in deionized water, respectively. As a control non-pH-responsive core polymer, we
also prepared lipid-enveloped PLGA nanoparticles by the emulsion/solvent evaporation
process, which had mean diameters of 445 ± 67 nm. Functionally, PBAE-core particles
prepared by either synthesis method exhibited indistinguishable endosomal disruption
capacities, RNA loading, and in vitro and in vivo transfection in subsequent assays, and thus
we report on data collected with particles prepared by both methods below.
Poly-1 is a weak polyelectrolyte that is water insoluble at elevated pH but ionizes and
dissolves in aqueous solutions below pH ~7. This selective solubility has been exploited to
promote cytosolic delivery of drug cargos following uptake by cells.51 Theoretically, once
internalized by cells, particles containing this polymer can trigger disruption of the
endosomal membrane by at least two (non-exclusive) mechanisms: (i) via a strong osmotic
pressure gradient generated across the endosomal membrane as the solid PBAE particles
dissolve into individual polymer chains52; (ii) via an osmotic pressure buildup due to
buffering of acidification by the charged polymer backbone and subsequent counterion
buildup in the endosome.53,54 We first verified the pH-responsiveness of “naked” PBAE
particles (lacking lipids and stabilized only by PVA) by measuring the 350 nm absorbance
of particle suspensions in 100 mM phosphate buffers of different pHs, using this absorbance
as a surrogate measure of particle light scattering. As shown in Figure 1D, intact particles
gave highly scattering milky suspensions at pH > 7.3, but became transparent solutions at
lower pHs modeling the acidic environment found within endosomes. Consistent with
earlier studies of poly-1 PBAE microparticles51, particle dissolution was rapid (within 5
min) upon exposure to acidic buffers. The same trend was observed for particles prepared
with lipid as surfactant, showing that the lipid coating did not alter the dissolution properties
of the particles. The presence of intact particles at pH > 7 and disappearance of particles at
acidic pH was confirmed by confocal microscopy (data not shown). We thus expect that
following acidification of endolysosomal compartments, mRNA on the particles would be
quickly released into the cytosol upon rapid build up of osmotic pressure triggered by
particle dissolution, thereby minimizing contact with acidic conditions inside
endolysosomes.
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To provide direct evidence for the assembly of the lipid coating at the surface of the
particles, we also imaged samples by cryoelectron microscopy. Similar to our prior findings
with PLGA particles prepared using lipids as a surface modifier37, we saw that PBAE
particles prepared by the emulsion/solvent evaporation process had electron dense lipid
bands coating the surfaces of the particles (Fig. 1D). Table 1 summarizes the size,
polydispersity indices (PDI) and zeta potentials of “naked” PBAE particles (PVA-stabilized
particles lacking lipid coating), lipid-coated PBAE particles with and without PEGylation,
and PEGylated particles following mRNA adsorption (~12–14 μg mRNA/mg particles
loaded, discussed below), all measured in deionized water, the medium used for particle
synthesis and mRNA loading. A positive zeta potential was measured in all cases and is
likely attributable to some degree of ionization of the PBAE core in deionized water (pH ~
5.5). In contrast with the pH-dependent solubility profile measured in Figure 1D in high
ionic strength buffers (100 mM phosphate buffers), particles remained stable in deionized
water despite its acidic pH. We hypothesize this reflects the lack of sufficient ionic strength
to fully ionize the core, which would otherwise lead to particle dissolution. At very low
ionic strength, polyelectrolyte ionization can be dramatically suppressed relative to the
expected equilibrium at high ionic strength.55–58 However, when particle zeta potentials
were measured in high ionic strength basic pH buffers where no ionization of the core is
expected, the zeta potentials of the particles were reduced accordingly (10 ± 4 mV and −7 ±
3 mV for non-PEGylated and PEGylated particles at pH 8, respectively).
Endosomal Escape by Lipid-coated PBAE Particles
To test the ability of lipid-enveloped PBAE particles to disrupt endosomes, calcein, a
membrane-impermeable fluorophore, was used as a tracer to monitor the stability of
endosomes59 following particle uptake by dendritic cells (DCs), a key cellular target of
interest for vaccine delivery.34,60 As shown in Figure 2A, DCs incubated with calcein alone
showed a punctate distribution of fluorescence indicative of endolysosomal
compartmentalization of internalized dye. In contrast, cells co-incubated with calcein and
fluorescently-tagged lipid-enveloped PBAE nanoparticles exhibited calcein fluorescence
throughout the cytosol and nucleus (at uniform high levels in both the cytosol and nucleus
due to free diffusion of cytosolic dye throughout intracellular compartments), suggesting
escape of calcein from intracellular vesicles following co-internalization of extracellular
fluid containing both dye and particles (Figure 2B, C). Calcein entry into the cytosol
triggered by the presence of nanoparticles required the PBAE core, as calcein remained in an
endosomal distribution in cells co-incubated with calcein and lipid-enveloped PLGA
particles (Figure 2D).
To quantitatively compare the endosomal disruption capability of PBAE-core particles vs.
PLGA-core particles vs. calcein alone in the entire cell population, cells given various
treatments were collected following trypsinization and their calcein fluorescence intensity
was measured via flow cytometry. Cells incubated with calcein alone showed a
homogeneous shift to increased green fluorescence (Figure 2E, F). In contrast, cells co-
incubated with calcein and lipid-enveloped PBAE NPs showed two populations of calcein+
cells: a calceinlow and calceinhigh population (Figure 2E, F). Calcein, when trapped within
endosomes, can be quenched via 2 mechanisms: self-quenching due to concentration of the
dye in endolysosomes61, and quenching due to calcein’s sensitivity to pH in the
endolysomal pH range62. Thus, the net fluorescence of a given quantity of internalized
calcein and other pH-sensitive dyes is seen to increase on release from endolysosomes, a
phenomenon reported by several groups.63,64 We used this phenomenon to quantitate the
fraction of DCs showing endosome disruption on the population level, by scoring the
fraction of cells exhibiting bright calcein fluorescence beyond that observed for control cells
incubated with calcein alone (Figure 2F). As shown in Figure 2G, following a 1 h incubation
Su et al. Page 8
Mol Pharm. Author manuscript; available in PMC 2012 May 17.
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
with PBAE particles, ~50% of the cell population showed an enhanced calcein intensity in
accordance with the cytosolic/nuclear distribution of calcein, compared to ~0% of cells
incubated with calcein alone or calcein + PLGA particles.
To confirm that endocytosis of the nanoparticles/calcein was required for calcein delivery to
the cytosol, we incubated DCs with calcein and nanoparticles at 4 °C to block endocytosis
and found that neither calcein nor nanoparticles were internalized by cells up to 3 h at 4 °C
(data not shown). This suggests that calcein/nanoparticle uptake and calcein entry into the
cytosol of DCs required the active process of endocytosis and excluded the possibility of
calcein de-quenching due to nanoparticle fusion with the plasma membrane.
Cytotoxicity of Lipid-coated PBAE Particles
Polycations used for intracellular delivery are notorious for their toxicity;65–67 thus we next
analyzed the toxicity of this lipid-enveloped particle delivery system. We incubated DC2.4
cells with lipid-enveloped poly-1 particles or “naked” PVA-stabilized poly-1 particles
prepared by emulsion/solvent evaporation synthesis for 1 h or 12 h, and subsequently
stained with annexin V and DAPI to identify cells undergoing apoptosis or necrosis,
respectively. PVA-stabilized Poly-1 NPs appeared less toxic than some other polycations
(e.g., polyethyleneimine, which is often reported to induce 50% cytotoxicity at
concentrations of ~20–30 μg/ml68), but still led to ~50% cell death after only an hour
incubation of cells with 100 μg/ml of the particles, and showed an LD50 between 75 and
100 μg/ml for longer incubations of 12 h. Lipid-enveloped PBAE NPs, irrespective of
PEGylation, showed lower toxicity at both time-points across all tested particle
concentrations (Figure 3); notably, particle concentrations that promoted robust endosome
disruption by the calcein assay (75 μg/ml) showed low toxicity at both time points. Thus,
the lipid shell achieved the desired effect of mitigating toxicity of the poly-1 polymer core.
RNA Loading onto Particle Surfaces
Loading of RNA cargos on these lipid-enveloped particles by adsorption post synthesis
provided a means to avoid exposing RNA to harsh processing conditions. Although
encapsulation of nucleic acids is often pursued in order to protect these compounds from
premature enzymatic degradation in vivo, prior studies where plasmid DNA was
electrostatically adsorbed to charged PLGA microparticles showed that particle-adsorbed
DNA had a greatly increased half-life in vivo compared to naked plasmids69, suggesting that
simple adsorption to particle surfaces may sterically protect polynucleic acids from
nucleases. We hypothesized that loading of RNA onto the particle surfaces would increase
bioavailability of the RNA by allowing faster release in cells, while avoiding exposure of the
polynucleotides to the acidic/hydrophobic environment inside degrading particles that would
be expected if we encapsulated RNA within the particle cores. To assess the efficiency of
electrostatic adsorption for loading of RNA on surfaces of lipid-coated PBAE particles, we
first quantified RNA binding to the particles as a function of time and RNA concentration
using poly I:C, a synthetic double-stranded RNA (dsRNA) with an average size of 0.2–1 Kb,
comparable in size to mRNA transcripts of interest. Poly I:C is an immunostimulatory
analog of viral dsRNA and activates innate immune cells through Toll-like receptor 370,71
and the cytosolic RNA sensor MDA-572,73, which further motivated these experiments. Poly
I:C was mixed with lipid-coated PBAE particles in nuclease-free water to allow RNA
binding, followed by washing to remove remaining unbound RNA. We found that RNA
binding equilibrated rapidly, reaching a plateau by 2 h when 4 μg of RNA was incubated
with 300 μg particles in 300 μl nuclease-free water (Figure 4A). Interestingly, PEGylated
particles also bound poly I:C to similar levels, suggesting that the PEG layer on the particle
surface did not prevent electrostatic attraction of the RNA to the charged lipid surfaces
(Figure 4A). We next measured binding of varying amounts of poly I:C added to a fixed
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concentration of 1 mg/ml particles, and saw that 1 mg of particles was capable of absorbing
up to 133 μg of RNA before binding was saturated (Figure 4B). However, we observed that
the particles exhibited increasing aggregation when higher RNA concentrations were used
(not shown), likely due to the bridging of particles by RNA. To compare poly I:C and
mRNA loading, we used single-stranded mRNA transcripts encoding GFP or luciferase.
Fixing the mass of particles at 300 μg and RNA at 4 μg in 300 μl of nuclease free water,
both poly I:C and mRNA bound to particles with over 95% efficiency (Figure 4C, D)
without inducing substantial aggregation (Figure 4E), resulting in ~12–14 μg of RNA
loading per mg of particles, a total loading comparable to other biodegradable particle
systems where polynucleotides were incorporated by either surface loading or encapsulation
in micro/nano-particles.74–76 This non-saturating level of mRNA loading on the particles did
not lead to a significant change in the zeta potential of the particles in deionized water
(Table 1); we believe this reflects the dominant role of the charge density present in the
partially-ionized PBAE core on the zeta potential of the particles.
To assess how well adsorbed RNA would remain bound to particles upon exposure to
physiological conditions, we measured the kinetics of poly I:C release from particles in
RPMI containing 10% serum at 37 °C. A burst release of approximately 30% of the poly I:C
desorbed within the first hour while the remaining RNA was gradually released over several
days (Figure 4F), suggesting that a significant amount of RNA would likely remained bound
onto the particles long enough for cellular uptake. Finally, we verified that mRNA coating
did not block the ability of lipid-enveloped poly-1 particles to disrupt endosomes, by
quantifying the fraction of DC2.4 cells exhibiting cytosolic/nuclear calcein following co-
incubation of cells with the dye and mRNA-loaded or unloaded particles for 1 h via flow
cytometry as discussed in the previous section. mRNA-loaded lipid-enveloped PBAE
particles trended toward slightly reduced endosome disruption compared to unloaded
particles, but this did not reach statistical significance (p >0.05) (Supporting information,
Figure S1). Thus, simple electrostatic adsorption allowed for rapid loading of the particles
with substantial quantities of RNA cargo, which could be retained on the lipid-coated poly-1
surface without blocking their endosome disruption activity.
A major issue for RNA-based therapeutics is their susceptibility towards nuclease
degradation. To determine if mRNA loaded onto the surface of lipid-enveloped PBAE
particles would be protected from nuclease degradation, we analyzed free or particle-bound
mRNA by gel electrophoresis following exposure to serum containing RNA nucleases. As
shown in Figure 4G, naked mRNA began to undergo degradation following as little as 5 min
exposure to buffer containing 2% FBS, and was almost entirely degraded within 1 h when
incubated with buffer containing 10% FBS (bright band detected at shorter fragment size
after 5 min incubation and no bands after 1 h incubation) compared to untreated mRNA
(cntl). In contrast, minimal degraded fragments were detected for particle-loaded mRNA,
where the majority of the nucleic acid remained intact on the particles following nuclease
treatment (trapped in the loading wells, top band of the gel), suggesting that mRNA
adsorbed onto the particles was protected from immediate nuclease activity.
Transfection of DCs with Lipid-coated PBAE Particles In Vitro
For an mRNA vaccine, these lipid-coated PBAE particles need to deliver intact mRNA into
the cytosol of antigen presenting cells such as DCs, where it can then be translated into
protein antigens for processing and presentation. Dendritic cells are notoriously difficult to
transfect and nonviral transfection agents generally achieve only 10–35% average
transfection of these cells in vitro.31–33
To visualize directly that mRNA loaded onto lipid-enveloped poly-1 particles was capable
of escaping endosomes to access the cytosol in dendritic cells, we imaged DCs incubated
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with labeled mRNA and LysoTracker tracer to stain the endolysosomal compartments, and
examined the intracellular trafficking of mRNA loaded onto particles compared to naked
mRNA. When DCs were incubated with naked mRNA in serum-free medium, we observed
colocalization of labeled mRNA with endolysosomes (Figure 5A). In contrast, particle-
delivered mRNA fluorescence was detected in regions of the cell outside endolysosomes,
providing direct evidence of the escape of particles and mRNA from endosomes into the
cytosol (Figure 5B). Notably, when naked mRNA was incubated with DCs in complete
medium containing 10% FBS, no mRNA fluorescence could be detected in the cells (data
not shown), indicating the labile mRNA is readily degraded in the presence of serum
nucleases without protection from the particles.
We then tested transfection of DCs in vitro by lipid-enveloped poly-1 particles in the
presence of serum, as a precursor to in vivo transfection studies. DC2.4 cells were incubated
with Cy3-labeled mRNA encoding for green fluorescence protein (GFP); mRNA was added
to the cells in soluble form or adsorbed to fluorescently-tagged lipid-enveloped NPs. Using
this set of fluorescence markers, mRNA, NPs, and translated protein (GFP) were
simultaneously traced in live cells. Naked mRNA is extremely labile in serum-containing
medium, and in fact essentially no intact mRNA was seen to be taken up by DCs in this
study when added to the cells in serum-containing medium (Figure 5C), though some uptake
was detected in serum-free medium, data not shown). In contrast, mRNA loaded on poly-1
NPs was efficiently delivered into the cells (Figure 5C), supporting the contention that
particle adsorption protected the RNA from serum nucleases. Further, a fraction of the cells
clearly expressed GFP at the 12 h timepoint (Figure 5C). Quantifying the results via flow
cytometry analysis, we found that particles were taken up by 80% of the cells and a similar
fraction of the cells internalized mRNA (Figure 5D–F). Looking at protein expression,
~30% of the total cells expressed GFP (Figure 5G, H), a frequency comparable to many
prior best reports of DC transfection in the literature.31–33 Irvine et. al compared transfection
efficiences in human monocyte-derived DCs using a cationic peptide-plasmid DNA
complex with a series of commercial nonviral agents at optimized conditions including
lipofectin, lipofectamine and DOTAP lipid where they demonstrated a superior average
transfection efficiency of 17% using a reporter GFP protein compared to 1–3% by
commercial agents. Aswathi et. al also reported similar transfection efficiency in JAWS II
dendritic cells (derived from the bone marrow of C57/BL6 mice) using a nonviral non-
liposomal lipid polymer, TransIT-TKO reagent. Strobel et. al reported transfection efficacy
of up to 20% when GFP RNA was delivered to monocyte-derived human DCs using
commercial liposomal formulations. In contrast to our experiments where transfection was
tested in the presence of serum, dendritic cells were incubated with nonviral transfection
agents in serum-free medium in each of these prior studies, limiting translation of the results
to conditions in vivo.
Particle uptake and GFP expression was similar for both PEGylated and non-PEGylated
particles (Figure 5D, H). Notably, under these conditions providing 30% transfection, the
particles were non-toxic and >95% of the cells were negative for DAPI and annexin V (data
not shown).
In Vivo Transfection with Lipid-coated PBAE Particles
Finally, we tested lipid-coated PBAE particles loaded with mRNA encoding for luciferase
protein in vivo, since many systems that transfect cells in vitro fail to function or have
serious toxicity in vivo. Intranasal delivery is a convenient and effective route of mucosal
vaccination, where the development of antigen particulate carrier systems is of considerable
interest.77–80 For vaccine applications, administration via mucosal surfaces is an attractive
route for inducing a protective immune response since most pathogens invade the body
through mucosal surfaces. Mucosal immunization elicits both systemic and mucosal
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immunity81,82, while the latter is usually not achieved via parenteral administration. It has
also been established that mucosal vaccines administered at one site can elicit an immune
response in mucosal tissues remote from the site of initial antigen exposure, mediated by
trafficking of effector immune cells between mucosal tissue compartments.83,84 Although
parenteral injections of naked mRNA in vivo have been reported in both preclinical models
and early clinical trials to elicit protein expression and immune responses1,4,85,23,24, it was
not clear if naked mRNA administration would be effective when administered via a non-
invasive route such as intranasal delivery, where the mRNA may need to traverse both the
epithelial layer and the overlying mucus barrier layer to access target cells. In nasal
inoculation, particulate antigens can be taken up by M-cells of nasal-associated lymphoid
tissue (NALT), where they are processed and preferentially directed to the antigen-
presenting cells, in contrast to soluble antigen.86–88,77,79 It has been demonstrated that
particulate delivery systems, particularly those bearing cationic charges, can enhance muco-
adhesiveness, reducing the clearance rate from the nasal cavity, and thereby increasing the
contact time of the delivery system with the nasal mucosa, facilitating transport.77,79,80
Luciferase-encoding mRNA (4 μg), in soluble form or adsorbed to 150 μg DiD-labelled
NPs, was administered intranasally to anesthetized C57BL/6J mice, and the presence of
particles and luciferase expression were tracked longitudinally via fluorescence and
bioluminescence imaging in live animals (Figure 6). Immediately following intranasal
administration, localized particle fluorescence was detected in the nasal region, but
fluorescence above background could not be detected by 6 h (Figure 6A, B), suggesting that
the particles are rapidly cleared from the nasal passage. However, at 6 h after administration,
significant bioluminescence (p <0.01 vs. untreated animals) could be detected at the
inoculation site, demonstrating successful transfection by mRNA-loaded particles, while
mice treated with naked mRNA showed no signal above background (Figure 6D). Imaging
at later time points revealed that the luciferase activity peaked at 12 h before declining to
background levels 24 h after administration, consistent with the expected short half-life of
transfected mRNA in vivo.1,85 At 12 h, although bioluminescence was detected in some
mice receiving naked mRNA, expression was observed in all mice treated with particles
(statistically significant above naked mRNA treatment group, p <0.05), demonstrating that
lipid-enveloped poly-1 NP delivery was more effective and consistent in eliciting protein
expression in vivo (Figure 6C, D). Significant variations in levels of transfection were
consistently observed for naked mRNA-treated mice in multiple independent experiments,
reflected in the increased variance in bioluminescence signal detected at the peak of protein
expression at 12 h (st.dev.naked = 2500 vs. st.dev.NP = 1200). Generally, 1–2 mice/group
always failed to respond to naked mRNA administration, possibly reflecting a fundamental
limitation in the consistency of transfection efficiency of naked mRNA by this route,
compared to nanoparticle administration where all mice were transfected. Though more
detailed safety analyses are a topic for future study, PBAE nanoparticles did not elicit overt
signs of toxicity in mice: no signs of granuloma formation or chronic inflammation were
observed at i.n. or parenteral administration sites, nor were changes in the body mass or
behavior of mice detected up to 3 months following particle administration (data not
shown).
Altogether, these data show that cytosolic delivery of mRNA is achieved by this lipid-
enveloped NP delivery system both in vitro and in vivo with minimal toxicity, via the
electrostatic adsorption of cargo molecules to the particle surfaces. RNA bound to these pH-
sensitive particles was protected from serum nucleases and facilitated in vivo transfection.
This approach provides a simple strategy to enhance mRNA delivery of interest for mRNA
vaccine design, and may be useful for other instances where local gene delivery may be of
therapeutic value.
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Figure 1.
Design and characterization of lipid-enveloped PBAE particles. (A) Schematic of structure
and composition of lipid-coated PBAE particles and mRNA cargo association. (B, C) Size
histograms of particles prepared via nanoprecipitation (B) or emulsion/solvent evaporation
(C) methods. (D) Measurement of absorbance of particle suspensions as a function of
solution pH for both lipid and PVA stabilized particles. (E) Representative cryoEM image of
lipid-enveloped PBAE particles, showing the presence of the lipid coating at the particle
surfaces (scale bar = 50 nm).
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Figure 2.
pH-responsive lipid-enveloped PBAE particles chaperone the delivery of the membrane-
impermeable dye molecule calcein into the cytosol of dendritic cells. DC2.4 cells were
incubated for 1 h with calcein alone or calcein and lipid-coated poly-1 or PLGA particles,
washed to remove unbound particles, then imaged live by confocal microscopy (A–D) or
analyzed by flow cytometry (E–G). Confocal images of DC2.4 cells incubated with calcein
alone (A) or calcein and lipid-coated PBAE particles (B) (LHS = fluorescence overlays: red,
nanoparticles; green, calcein. RHS = bright-field images). (C, D) Cells co-incubated with
calcein and either lipid-coated PBAE particles (C) or lipid-coated PLGA particles (D) (LHS
= Green, calcein. RHS = bright-field images). Representative images of PEGylated particles
are shown here, but a similar trend was observed with non-PEGylated particles. Flow
cytometry scatter plots of particle fluorescence vs. calcein fluorescence (E) and histograms
(F) for cells treated with calcein or calcein + PBAE particles compared with untreated
control cells or cells incubated with particles alone. (G) Average percentage of cells
exhibiting cytosolic/nuclear calcein distribution after 1 h incubation with lipid-coated PBAE
particles or lipid-coated PLGA particles compared to calcein-only control. Shown are the
mean ± SD from triplicate samples.
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Figure 3.
Assessment of nanoparticle cytotoxicity. DC2.4 cells were incubated with increasing doses
of PEGylated or non-PEGylated lipid-coated poly-1 particles, or PVA-stabilized poly-1
particles for 1 h or 12 h at 37 °C, washed, detached and then stained with DAPI and annexin
V to detect apoptotic and necrotic cells by flow cytometry. Shown are the percentages of
live (DAPI− annexin V−) cells relative to untreated controls. Error bars represent standard
deviation of triplicate samples.
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Figure 4.
RNA adsorption to PEGylated or non-PEGylated lipid-coated PBAE particles in water. (A)
Kinetics of poly I:C adsorption to lipid-coated PBAE particles for 300 μg particles
incubated with 4 μg RNA in 300 μl of water. (B) Binding of Poly I:C at varying
concentrations to 300 μg particles in 300 μl of water for 2 h. (C, D) Binding efficiency (C)
and RNA loading (D) of mRNA or poly I:C assessed for RNA (4 μg) added to 300 μg
particles for 2 h in 300 μl of water. (E) Size histograms of particles before and after mRNA
adsorption at optimized loading conditions (4 μg mRNA added to 300 μg particles in 300 μl
of water). (F) Release of poly I:C from nanoparticles incubated in RPMI medium containing
10% FBS at 37 °C. (G) 1 μg mRNA (either free mRNA (Naked) or bound to PEGylated
PBAE nanoparticles (NP)) was incubated with 2 or 10% FBS for 5 min or 1 h at 37 °C (or
left untreated, Cntl) and analyzed by electrophoresis on a 1% agarose gel. Upper panel
shows mRNA detected in the loading wells when mRNA was loaded onto particles and
lower panel shows intact free mRNA (Cntl) and degraded mRNA fragments obtained when
samples were exposed to serum nucleases. Naked mRNA is completely destroyed by 1 h
when exposed to 10% FBS.
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Figure 5.
Lipid-coated PBAE particles mediate cytosolic mRNA delivery and transfection in dendritic
cells in vitro. (A, B) To observe cytosolic mRNA delivery, DC2.4 cells were incubated for
1h in the presence of LysoTracker green to stain endolysosomes (green) and either naked
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Cy3-labeled mRNA (red) in serum-free Opti-mem (A) or Cy3-labeled mRNA loaded on
particles in complete medium (10% FBS) (B). To study transfection, DC2.4 cells were
incubated for 12 h in complete medium (10% FBS) with either naked mRNA (1 μg/ml) or
an equivalent dose of mRNA adsorbed to PEGylated or non-PEGylated lipid-coated PBAE
particles (75 μg particles/ml), then washed and imaged live by confocal microscopy at 37 °C
or analyzed by flow cytometry. (C) Confocal images of DiD-labeled particles (blue), Cy3-
labeled mRNA (red), and GFP expression (green) with fluorescence/bright-field overlays in
DC2.4 cells. (D–H) Flow cytometry analysis of DC2.4 cells showing mean particle uptake
(D), representative histograms of fluorescent mRNA uptake (E) and mean frequency of
mRNA+ cells (F), representative cytometry histograms of GFP expression (G), and mean
frequency of GFP+ cells (H). Shown are means ± SD from duplicates in 2 independent
experiments.
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Figure 6.
In vivo transfection in C5BL/6J mice following intranasal administration of firefly
luciferase-encoding mRNA either in soluble form or adsorbed on fluorescent lipid-
enveloped PBAE particles. (A) Fluorescence image of mice immediately following
intranasal particle administration. (B) Total fluorescence signal at the inoculation site at 0
and 6 h quantified from groups of particle-treated or control mice. (C) Bioluminescence
images of mice 12 h following mRNA administration. (D) Bioluminescence signal at the
inoculation site at 6, 12 and 24 h quantified from groups of treated and control mice. ***,p
<0.001, **, p <0.01 and *, p <0.05. Data shown from one representative of two independent
experiments (n = 4 mice/group).
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Table 1
Size and zeta potentials of PBAE nanoparticles determined by dynamic light scattering.
Sample Effective Diameter (nm) PDI Zeta Potential in deionized water (mV)
PVA NP 300 ± 50 0.141 ± 0.08 32 ± 8
Non-PEGylated lipid-coated NP 250 ± 45 0.120 ± 0.06 41 ± 10
PEGylated lipid-coated NP 230 ± 40 0.100 ± 0.05 42 ± 8
mRNA-loaded PEGylated lipid-coated NP 280 ± 70 0.182 ± 0.10 40 ± 7
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